CLAIM CARD
This synthesis maps 54 included sources on Retinal age AI across 7 outcome classes and 792 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.
Evidence grade: exploratory
Contradiction status: none
Publication: df81d398-48f0-4b72-9ba2-3a198be21ae8
Provenance: Derivation Web chain
Citation Support
source_1Nonaka 2026source_2Zhu 2023source_3Chen 2023source_4Chen 2025source_5Miao 2025